NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Analyst Earnings Estimates
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.622M 146.13% | 17.389M -46.70% | 12.082M -30.52% | 125.02M 934.76% | 332.67M 166.09% | 664.17M 99.65% | 1.054B 58.69% | 1.482B 40.61% | 1.82B 22.81% | |||
| EBITDA YoY % growth | -126.7K | -1.352M -967.32% | -3.867M -185.96% | -218.688M -5,555.24% | -192.78M 11.85% | -156.06M 19.05% | -105.06M 32.68% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -127.7K | -1.366M -969.93% | -3.939M -188.30% | -192.371M -4,783.75% | -190.345M 1.05% | -247.316M -29.93% | -252.202M -1.98% | -144.506M 42.70% | -53.643M 62.88% | 171.15M 419.05% | 517.37M 202.29% | 829.24M 60.28% | 1.005B 21.20% | |
| Operating Margin | N/A | N/A | -4.04% | -1,451.42% | -583.49% | -1,422.26% | -2,087.42% | -115.59% | -16.13% | 25.77% | 49.09% | 55.95% | 55.22% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.12 -16.91% | -1.85 28.15% | -2.14 -15.26% | -1.28 40.15% | -0.53 58.72% | 1.28 342.44% | 3.30 158.10% | 4.53 37.20% | 6.03 33.11% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -22.32% | -0.48 -166.33% | -0.53 43.42% | -0.50 -48.20% | -0.50 1.02% | -0.52 -7.80% | -0.53 -1.44% |
| Revenue Q2Q % growth | 1.63M -28.48% | 4.399M -84.89% | 9.271M -27.41% | 110.16K -96.30% | 374.003K -77.06% | 612K -86.09% | 849.997K -90.83% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -65.23M -14.35% | -64.413M -22.69% | -62.241M -14.63% | -61.664M -6.12% | -55.622M 14.73% | -60.014M 6.83% | -66.214M -6.38% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.34 67.92% | -0.50 | 0.16 | 31.66% |
| Q4 2024 Q2Q % growth | -0.93 -60.07% | -0.50 | -0.43 | -87.61% |
| Q3 2024 Q2Q % growth | -0.18 67.54% | -0.51 | 0.33 | 64.67% |
| Q2 2024 Q2Q % growth | -0.41 11.09% | -0.59 | 0.18 | 30.32% |
| Q1 2024 Q2Q % growth | -1.06 -163.31% | -0.54 | -0.52 | -97.14% |
| Q4 2023 Q2Q % growth | -0.58 -26.72% | -0.61 | 0.03 | 4.67% |
| Q3 2023 Q2Q % growth | -0.55 4.59% | -0.50 | -0.06 | -11.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 2.978M 112.56% | 1.607M | 1.371M | 85.31% |
| Q4 2024 Q2Q % growth | 12.772M 1,521.66% | 1.791M | 10.981M | 613.12% |
| Q3 2024 Q2Q % growth | 29.111M 877.73% | 1.91M | 27.201M | 1,424.14% |
| Q2 2024 Q2Q % growth | 2.279M -76.17% | 1.406M | 873K | 62.09% |
| Q1 2024 Q2Q % growth | 1.401M -45.10% | 1.778M | -377K | -21.20% |
| Q4 2023 Q2Q % growth | 787.59K -99.19% | 1.998M | -1.21M | -60.58% |
| Q3 2023 Q2Q % growth | 2.977M | 2.291M | 686.42K | 29.96% |
| Q2 2023 Q2Q % growth | 9.562M | 2.794M | 6.768M | 242.23% |
| Q4 2022 Q2Q % growth | 97.5M | 3.561M | 93.939M | 2,637.99% |
| Q3 2022 Q2Q % growth | 1.687M | -1.687M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -16.39% |
| Revenue | 0% | 0% | 0% | 86.41% |